In a significant boost for 23andMe, the Food and Drug Administration has allowed the direct-to-consumer genetics Silicon Valley startup to use its kit to test for a serious genetic disorder known as Bloom Syndrome.
In November 2013, the FDA ordered 23andMe to stop marketing and selling its kits as a way to test for genetic health information. This marks the first time the FDA has allowed for a home “carrier screening” genetic test. (Ars examined the state of direct-to-consumer genetic testing in April 2014.) Since the 2013 ban, 23andMe customers could only use the service as a way to find out more about their genealogy.
According to the National Institutes of Health, Bloom Syndrome “is an inherited disorder characterized by short stature, sun-sensitive skin changes, an increased risk of cancer, and other health problems.”
Read 3 remaining paragraphs | Comments

Leave a Reply